The diffuse nuclear immunoreactivity for STAT6 by immunohistochemistry is consistent with this tumour type’s underlying NAB2–STAT6 fusion characteristic.1 STAT6 immunoexpression on tumour cells can distinguish SFT from its histological mimics.3 Additional TERT promoter and TP53 alterations have been associated with aggressive behaviour and dedifferentiation.1 This evidence concerns the gene STAT6 and neoplasm.